These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 15486991

  • 1. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G.
    Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991
    [Abstract] [Full Text] [Related]

  • 2. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF, Wang Y, Cho JY, Libermann TA.
    Cancer Res; 2003 May 01; 63(9):2206-15. PubMed ID: 12727841
    [Abstract] [Full Text] [Related]

  • 3. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.
    Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G.
    Prostate; 2008 Jun 15; 68(9):924-34. PubMed ID: 18386285
    [Abstract] [Full Text] [Related]

  • 4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 6. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.
    Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234
    [Abstract] [Full Text] [Related]

  • 7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 8. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 9. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 10. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
    Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH.
    J Androl; 2008 Oct 15; 29(6):661-8. PubMed ID: 18676361
    [Abstract] [Full Text] [Related]

  • 11. AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells.
    Qi H, Fillion C, Labrie Y, Grenier J, Fournier A, Berger L, El-Alfy M, Labrie C.
    Cancer Res; 2002 Feb 01; 62(3):721-33. PubMed ID: 11830526
    [Abstract] [Full Text] [Related]

  • 12. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 13. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
    Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL, Shemshedini L.
    Oncogene; 2006 Nov 16; 25(54):7212-23. PubMed ID: 16732317
    [Abstract] [Full Text] [Related]

  • 14. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 15. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity.
    Hilfiker-Kleiner D, Hilfiker A, Castellazzi M, Wollert KC, Trautwein C, Schunkert H, Drexler H.
    Cardiovasc Res; 2006 Jul 01; 71(1):108-17. PubMed ID: 16690042
    [Abstract] [Full Text] [Related]

  • 16. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L, Giocanti N, Hennequin C, Favaudon V.
    Prostate; 2010 Mar 01; 70(4):401-11. PubMed ID: 19902473
    [Abstract] [Full Text] [Related]

  • 17. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 18. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
    Peternac D, Klima I, Cecchini MG, Studer UE, Thalmann GN.
    J Urol; 2006 Jul 01; 176(1):354-60. PubMed ID: 16753443
    [Abstract] [Full Text] [Related]

  • 19. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 20. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.